Oxytocin in MRI-HIFU

Conditions

Adenomyosis, Fibroid

Keywords

oxytocin, MRI-HIFU, fibroid, adenomyosis

Brief summary

Capability of oxytocin in improving the efficacy of MRI-HIFU is studied. Patients undergoing MRI-HIFU treatment are given oxytocin during treatment and the efficacy of the treatment will be analysed by patient reported symptom questionnaires and imaging data.

Saara Otonkoski, Antti Viitala, Gaber Komar, Teija Sainio, Anna Yanovskiy et al. (8 authors)

Acta Obstetricia Et Gynecologica Scandinavica2025-04-293 citations

10.1111/aogs.15086

Oxytocin selectively reduces blood flow in uterine fibroids without an effect on myometrial blood flow: a dynamic contrast enhanced MRI evaluation.

Otonkoski S, Sainio T, Komar G, Suomi V, Saunavaara J, Blanco Sequeiros R, Perheentupa A, Joronen K.

2020-01-0112 citations

10.1080/02656736.2020.1846792

Interventions

DRUGOxytocin

Oxytocin infusion during MRI-HIFU treatment

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients undergoing MRI-HIFU -treatment * Patients assessed for suitability to MRI-HIFU treatment * willingness to participate in trial

Exclusion criteria

* Known allergy to Syntocinon/oxytocin * Elevated blood pressure * ischemic heart disease * Long QT- interval

Design outcomes

Primary

Measure	Time frame	Description
NPV	up to one year	non perfused volume (percentage of fibroid destroyed)
duration of MRI-HIFU	up to one year	duration of MRI-HIFU treatment
UFS-Qol	12 months after HIFU treatment	Uterine fibroid symptom severity and quality of life (patient quality of life questionnaire)

Countries

Finland

Outcome results

None listed